Insights from LSI USA ‘24: Stryker’s Journey to $20 Billion and the Role of M&A
Stryker’s long-term commitment to M&A has been a cornerstone of its growth strategy. Bryant Zanko, who leads corporate business development at Stryker, emphasized this commitment: “M&A has really been in our DNA. If you look at most of our divisions, the nucleus of that was an acquisition.” This long-term perspective has allowed Stryker to continually expand and innovate, leveraging acquisitions to build a robust portfolio across various healthcare segments. The focus on M&A strategy was driven by the recognition that acquisitions can be a powerful tool for achieving growth and maintaining a competitive edge in the medtech industry. For more information visit https://issuu.com/lsiusa25/doc....s/insights_from_lsi_
